Table 3.

Variation in use of Bevacizumab across practices: odds of use for a patient seen in a moderately-high-use practice (+1 SD) versus a moderately-low-use practice (−1 SD)

Cohort	Odds Ratio (95% CI) of Bevacizumab Use in Moderately-High-Use Practice vs. a Moderately-Low-Use Practice
All cancers, all practices	2.90 (2.73–3.08)
All cancers, higher-value use*	2.72 (2.56–2.89)
All cancers, lower-value use*	3.61 (3.21–4.06)
All cancers, approved cancer type†	2.68 (2.52–2.85)
All cancers, non-approved cancer type†	4.13 (3.60–4.74)
All cancers, large practices	2.47 (2.35–2.61)
All cancers, small practices	4.04 (3.47–4.70)
Colorectal cancers	2.39 (2.23–2.55)
Breast cancers	3.35 (2.83–3.97)
Lung cancers	4.01 (3.54–4.54)
Brain cancers (glioblastoma)	3.52 (1.45–8.59)
Kidney cancers	3.33 (2.11–5.25)
Ovarian cancers	3.74 (2.92–4.78)

^*Higher-value use defined as use for cancers after evidence of an overall survival benefit has been documented. This was all times during the study period for colorectal cancer patients and after May 2005, when evidence of benefit was presented at the American Society of Clinical Oncology Annual Meeting. Lower-value use is all other use.

^†Approved cancer type reflects use during a time period when the drug was approved by the FDA for that cancer type. Non-approved use is all other cancer types.